Feed Skupnost
CF
Carlos Fernández
@carlosf · Jan 17

Novo Nordisk $NVO – My largest equity position and why I hold it

Novo Nordisk ($NVO) is my largest equity position, making up 11.5% of the portfolio value with an unrealized gain of 31.29%. As a leader in diabetes and obesity treatment (e.g., Ozempic and Wegovy) it’s on an upward trend – it rose 9.12% on January 16, 2026, closing at $62.33. I plan to hold it long term because of its growth potential.

Strategy: Target price $65. If it exceeds $71.50, I’ll set a trailing stop loss starting at $65 to lock in gains and benefit from further upside.

Is it wise? Yes, it fits a trend-following approach with risk management.

Alternatives: Partial sales to rebalance the portfolio.

Positives:

High demand for GLP-1 drugs and for an oral form of Wegovy. Strong EPS and ROE growth creates real company value. Resilient healthcare sector.

Negatives:

High profits attract competition from generics manufacturers. Regulatory/legal issues can significantly increase volatility.

Your thoughts on $NVO – hold with a TSL or sell some off?

RN
Roman Nejtek @romannejtek Jan 18

For me, holding with a trailing stop loss makes sense. The trend is strong and fundamentals still support the story. I’d consider a partial sell only for portfolio rebalancing, not because the NVO thesis is breaking. Competition and regulation are real risks, but that’s fairly standard in this sector.

JM
Jonas Müller @jonasm Jan 18

You timed that purchase well, and I think you’re one of the few who aren’t at a loss 😂. I’m still holding the shares and I won’t sell until it gets above $100.

AT
Akira Tanaka @akirat Jan 17

I wouldn’t get rid of it. I own it too and I think the oral variant they launched on January 9, 2026, and the fact that it’s widely available will bring them a lot of customers. Many people have trouble giving themselves injections. For Q1 they’re still the only ones. Competitor $LLY will bring a pill version to market in April.

I own both companies and I’d like to proceed as follows

- wait for the development of $NVO shares (65–70 USD seems low to me), which will benefit from a temporary market advantage

- I therefore expect a decline in $LLY, an outflow of investors to the competitor

- from selling part of the $NVO position I would then buy more $LLY

Each company has its own version, but Lilly’s variant is more effective (two-component). However, Novo also has a two-component drug that is currently in phase 3 clinical trials and should be more effective, i.e. weight loss >20%. Current preparations are around 15%.

There’s one more factor: the exclusivity period for the injectable weight-loss drugs will expire and generic manufacturers are lining up to target them, so that portion of profits will disappear for both companies.